Evaluation of candidate methylation markers to detect cervical neoplasia

Gynecologic Oncology

Volumn 107, Issue 3, 2007, Pages 549-553

  Shivapurkar, Narayan ^a   Sherman, Mark E ^b   Stastny, Victor ^a   Echebiri, Chinyere ^a   Rader, Janet S ^c   Nayar, Ritu ^d   Bonfiglio, Thomas A ^e   Gazdar, Adi F ^a   Wang, Sophia S ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Cervical cancer; Promoter methylation; Tumor suppressor genes

Indexed keywords

CYTOKINE RECEPTOR; DEATH ASSOCIATED PROTEIN KINASE; HEPARAN SULFATE DEXTRO GLUCOSAMYL 3 O SULFOTRANSFERASE 2; SULFOTRANSFERASE; SUPPRESSOR OF CYTOKINE SIGNALING 3; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR 3; UNCLASSIFIED DRUG; UVOMORULIN;

ARTICLE; CONTROLLED STUDY; CYTOLOGY; HUMAN; HUMAN TISSUE; METHYLATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU;

ADENOCARCINOMA; CADHERINS; CARCINOMA, SQUAMOUS CELL; CERVICAL INTRAEPITHELIAL NEOPLASIA; DNA METHYLATION; FEMALE; GENES, TUMOR SUPPRESSOR; GENETIC MARKERS; HUMANS; POLYMERASE CHAIN REACTION; UTERINE CERVICAL NEOPLASMS;

EID: 36348989016     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2007.08.057     Document Type: Article

References (29)

1. Pisani P., Bray F., and Parkin D.M. Estimates of the world-wide prevalence of cancer for 25 sites in the adult population. Int J Cancer 97 (2002) 72-81
2. Wang S.S., Sherman M.E., Hildesheim A., Lacey Jr. J.V., and Devesa S. Cervical adenocarcinoma and squamous cell carcinoma incidence trends among white women and black women in the United States for 1976-2000. Cancer 100 (2004) 1035-1044
3. Kulasingam S.L., Hughes J.P., Kiviat N.B., Mao C., Weiss N.S., Kuypers J.M., et al. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. JAMA 288 (2002) 1749-1757
4. Bulkmans N.W., Berkhof J., Bulk S., Bleeker M.C., van Kemenade F.J., Rozendaal L., et al. HPV type-specific clearance rates in cervical screening. Br J Cancer 96 9 (2007) 1419-1424
5. Laird PAW. The power and the promise of DNA methylation markers. Nat Rev Cancer 3 (2003) 253-266
6. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2 (2002) 420-430
7. Kogel D., Prehn J.H., and Scheidtmann K.H. The DAP kinase family of pro-apoptotic proteins: novel players in the apoptotic game. Bioessays 23 (2001) 352-358
8. Nicholson S., De Souza D., Fabri L.J., Corbin J., Willson T., Zhang J.G., et al. Suppressor of cytokine signaling-3 preferentially binds to the SHP-2-binding site on the shared cytokine receptor subunit gp130. Proc Natl Acad Sci U S A 97 (2000) 6493-6498
9. Miyamoto K., Asada K., Fukutomi T., Okochi E., Yagi Y., et al. Methylation-associated silencing of heparan sulfate d-glucosaminyl 3-O-sulfotransferase-2 (3-OST-2) in human breast, colon, lung and pancreatic cancers. Oncogene 22 (2003) 274-280
10. Takeichi M. Morphogenetic roles of classic cadherins. Curr Opin Cell Biol 7 (1995) 619-627
11. Shivapurkar N., Takahashi T., Reddy J., Zheng Y., Stastny V., Collins R., et al. Presence of simian virus 40 DNA sequences in human lymphoid and hematopoietic malignancies and their relationship to aberrant promoter methylation of multiple genes. Cancer Res 64 (2004) 3757-3760
12. Herman J.G., Graff J.R., Myohanen S., Nelkin B.D., and Baylin S.B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 93 (1996) 9821-9826
13. Shivapurkar N., Stastny V., Suzuki M., Wistuba I.I., Li L., Zheng Y., et al. Application of a methylation gene panel by quantitative PCR for lung cancers. Cancer Lett 247 1 (2006) 56-71
14. Giroglou T., Florin L., Schafer F., Streeck R.E., and Sapp M. Human papilomavirus infection requires cell surface heparan sulfate. J Virol 75 3 (2001) 1565-1570
15. Humbert P., Caberg J.H., Gilles C., Bousarghin L., Franzen-Detrooz E., Boniver J., et al. E-cadherin-dependent adhesion of dendritic and Langerhans cells to keratinocytes is defection in cervical human papillomavirus-associated (pre)neoplastic lesions. J Pathol 206 3 (2005) 346-355
16. Hildesheim A., Hadjimichael O., Schwartz P.E., Wheeler C.M., Barnes W., Lowell D.M., et al. Risk factors for rapid-onset cervical cancer. Am J Obstet Gynecol 180 (1999) 571-577
17. Dong S.M., Kim H.S., Rha S.H., and Sidransky D. Promoter hypermethylation of multiple genes in carcinoma of the uterine cervix. Clin Cancer Res 7 (2001) 1982-1986
18. Sova P., Feng Q., Geiss G., Wood T., Strauss R., Rudolf V., et al. Discovery of novel methylation biomarkers in cervical carcinoma by global demethylation and microarray analysis. Cancer Epidemiol Biomarkers Prev 15 (2006) 114-123
19. Shivapurkar N., Toyooka S., Toyooka K.O., Reddy J., Miyajima K., Suzuki M., et al. Aberrant methylation of trail decoy receptor genes is frequent in multiple tumor types. Int J Cancer 109 (2004) 786-792
20. Virmani A.K., Muller C., Rathi A., Zoechbauer-Mueller S., Mathis M., and Gazdar A.F. Aberrant methylation during cervical carcinogenesis. Clin Cancer Res 7 (2001) 584-589
21. Steenbergen R.D., Kramer D., Braakhuis B.J., Stern P.L., Verheijen R.H., Meijer C.J., et al. TSLC1 gene silencing in cervical cancer cell lines and cervical neoplasia. J Natl Cancer Inst 96 (2004) 294-305
22. Li J., Zhang Z., Bidder M., Funk M.C., Nguyen L., Goodfellow P.J., et al. IGSF4 promoter methylation and expression silencing in human cervical cancer. Gynecol Oncol 96 (2005) 150-158
23. Feng Q., Balasubramanian A., Hawes S.E., Toure P., Sow P.S., Dem A., et al. Detection of hypermethylated genes in women with and without cervical neoplasia. J Natl Cancer Inst 97 (2005) 273-282
24. Kang S., Kim J.W., Kang G.H., Park N.H., Song Y.S., Kang S.B., et al. Polymorphism in folate- and methionine-metabolizing enzyme and aberrant CpG island hypermethylation in uterine cervical cancer. Gynecol Oncol 97 (2005) 173-180
25. Yang H.J., Liu V.W., Wang Y., Chan K.Y., Tsang P.C., Khoo U.S., et al. Detection of hypermethylated genes in tumor and plasma of cervical cancer patients. Gynecol Oncol 93 (2004) 435-440
26. Chan A.O., Soliman A.S., Zhang Q., Rashid A., Bedeir A., Houlihan P.S., et al. Differing DNA methylation patterns and gene mutation frequencies in colorectal carcinomas from Middle Eastern countries. Clin Cancer Res 11 (2005) 8281-8287
27. Yang, et al. Am J Pathol 163 (2003) 1101-1107
28. Yang B., Guo M., Herman J.G., and Clark D.P. Aberrant promoter methylation profiles of tumor suppressor genes in hepatocellular carcinoma. Am J Pathol 163 (2003) 1101-1107
29. Kosaka T., Yatabe Y., Endoh H., Kuwano H., Takahashi T., and Mitsudomi T. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 64 (2004) 8919-8923